Journal of Diagnostics Concepts & Practice >

2018 , Vol. 17 >Issue 06: 687 - 693

DOI: https://doi.org/10.16150/j.1671-2870.2018.06.012

Original articles

Analysis of KRAS, NRAS and BRAF mutations in colorectal cancer and their correlation with clinicopathologic features and p53 protein expression

Expand
  • Departments of Pathology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

Received date: 2018-08-16

  Online published: 2018-12-25

Fold

Abstract

Objective: To examine the mutation frequencies of KRAS, NRAS and BRAF in colorectal cancer (CRC) among Chinese population, and to investigate their correlation with clinicopathological parameters and p53 protein expression. Methods: Tissue samples and pathological data of 110 CRC patients undergoing surgical excision were collected, and the clinical pathological features were summarized. Mutations in KRAS (codon 12/13 at exon 2, codon 61 at exon 3 and codon 117/146 at exon 4), NRAS (codon 12/13 at exon 2, codon 61 at exon 3 and codon 146 at exon 4) and BRAF (codon 600 at exon 15) genes were examined with ARMS-PCR. p53 protein expression was detected by immunohistochemistry. Results: 45.4% (50/110) patients carried KRAS mutations; among them, almost all individuals had mutation in KRAS codon 12/13 at exon 2, except one individual had codon 117/146 at exon 4 mutated. 6.3% (7/110) patients carried NRAS mutations; among them, 3/110 patients had mutation in NRAS exon 2 (condon 12/13), 3/110 patients had mutation in NRAS exon 3 (condon 61), 1/110 patient had mutations in both NRAS exon 4 (condon 146) and KRAS. BRAF mutations were detected in 3 patients (2.7%), and were found to have V600E mutations. p53 expression was observed in 63 (57.3%) of 110 CRC patients. Within these 63 positive samples, 27 cases showed KRAS mutations, 7 cases showed NRAS mutations and 2 cases showed BRAF mutations. KRAS mutation was significantly associated with lymph node metastasis (P<0.05) while NRAS mutation was significantly associated with histological type and p53 protein expression (P<0.05). BRAF mutation was significantly associated with right colon cancer (P<0.05). Conclusions: KRAS is closely related to the molecular mechanism of occurrence and development of colorectal cancer. BRAF mutation is only found in right colon cancer, suggesting that the mechanism of right hemicolon cancer may have its particularity. The interaction between p53 protein expression and NRAS mutation is worthy of further study.

Key words： Colorectal cancer; KRAS; NRAS; BRAF; P53

Cite this article

WANG Ziyuan, LIANG Tingyu, CHEN Jia, HAN Zhihong, WU Lili . Analysis of KRAS, NRAS and BRAF mutations in colorectal cancer and their correlation with clinicopathologic features and p53 protein expression[J]. Journal of Diagnostics Concepts & Practice, 2018 , 17(06) : 687 -693 . DOI: 10.16150/j.1671-2870.2018.06.012

References

[1] Hanahan D, Weinberg RA.The hallmarks of cancer[J]. Cell,2000,100(1):57-70.
[2] Rajagopalan H, Nowak MA, Vogelstein B, et al.The significance of unstable chromosomes in colorectal cancer[J]. Nat Rev Cancer, 2003, 3(9):695-701.
[3] Peltomäki P.Mutations and epimutations in the origin of cancer[J]. Exp Cell Res,2012,318(4):299-310.
[4] Esteller M.Epigenetics in cancer[J]. N Engl J Med,2008, 358(11):1148-1159.
[5] 侯慧, 肖明明, 任秋华, 等. 结直肠癌中p53蛋白和Ki67的表达及临床意义[J]. 实用肿瘤学杂志,2008,22(5):424-426.
[6] Li Y, Xu KP, Jiang D, et al.Relationship of Fas, FasL, p53 and bcl-2 expression in human non-small cell lung carcinomas[J]. Int J Clin Exp Pathol,2015,8(11):13978-13986.
[7] Phipps AI, Buchanan DD, Makar KW, et al.KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers[J]. Br J Cancer, 2013,108(8): 1757-1764.
[8] Cappuzzo F, Varella-Garcia M, Finocchiaro G, et al.Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients[J]. Br J Cancer,2008, 99(1):83-89.
[9] Baldus SE, Schaefer KL, Engers R, et al.Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases[J]. Clin Cancer Res,2010,16(3):790-799.
[10] Lurkin I, Stoehr R, Hurst CD, et al.Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes[J]. PLoS One,2010,5(1):e8802.
[11] Guedes JG, Veiga I, Rocha P, et al.High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer[J]. BMC Cancer,2013,13:169.
[12] Sidransky D, Tokino T, Hamilton SR, et al.Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors[J]. Science,1992,256(5053):102-105.
[13] McLellan EA, Owen RA, Stepniewska KA, et al. High frequency of K-ras mutations in sporadic colorectal adenomas[J]. Gut,1993,34(3):392-396.
[14] ZhangJ, ZhengJ, Yang Y, et al. Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases[J]. Sci Rep,2015,5:18678.
[15] 吴文辉, 肖隆斌, 汤友珍, 等. K-ras基因突变与结直肠癌生物学行为的关系[J]. 中国病理生理杂志,2009,25(11):2159-2162.
[16] Shen Y, Wang J, Han X, et al.Effectors of epidermal growth factor receptor pathway: the genetic profiling of KRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine[J]. PLoS One,2013,8(12):e81628.
[17] Ye JX, Liu Y, Qin Y, et al.KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients[J]. World J Gastroenterol,2015,21(5):1595-1605.
[18] Shimada Y, Kameyama H, Nagahashi M, et al.Comprehensive genomic sequencing detects important genetic differences between right-sided and left-sided colorectal cancer[J]. Oncotarget,2017,8(55):93567-93579.
[19] Gonsalves WI, Mahoney MR, Sargent DJ, et al. Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147[J]. J Natl Cancer Inst,2014,106(7):pii: dju106.
[20] Downward J.Targeting RAS signalling pathways in cancer therapy[J]. Nat Rev Cancer,2003,3(1):11-22.
[21] Zenonos K, Kyprianou K.RAS signaling pathways, mutations and their role in colorectal cancer[J]. World J Gastrointest Oncol,2013,5(5):97-101.
[22] Irahara N, Baba Y, Nosho K, et al.NRAS mutations are rare in colorectal cancer[J]. Diagn Mol Pathol,2010,19(3):157-163.
[23] Devitt B, Liu W, Salemi R, et al.Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma[J]. Pigment Cell Melanoma Res,2011,24(4):666-672.
[24] Yoon HH, Shi Q, Alberts SR, et al. Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage Ⅲ Colon Cancer Patients[J]. J Natl Cancer Inst,2015,107(10):pii: djv186.
[25] Baskin Y, Calibasi G, Amirfallah A, et al.KRAS and BRAF mutation frequencies in a series of Turkish colo-rectal cancer patients[J]. Transl Cancer Res,2014,3(2):160-166.
[26] Tie J, Gibbs P, Lipton L, et al.Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation[J]. Int J Cancer,2011,128(9):2075-2084.
[27] Samowitz WS, Albertsen H, Sweeney C, et al.Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer[J]. J Natl Cancer Inst,2006,98(23):1731-1738.
[28] Bhalla A, Zulfiqar M, Bluth MH.Molecular Diagnostics in Colorectal Carcinoma: Advances and Applications for 2018[J]. Clin Lab Med,2018,38(2):311-342.
[29] Yokota T, Ura T, Shibata N, et al.BRAF mutation is a powerful prognostic factor in advanced and recurrent colo-rectal cancer[J]. Br J Cancer,2011,104(5):856-862.
[30] Lai E, Pretta A, Impera V, et al.BRAF-mutant colorectal cancer, a different breed evolving[J]. Expert Rev Mol Diagn,2018,18(6):499-512.
[31] Muller PA, Vousden KH.Mutant p53 in cancer: new functions and therapeutic opportunities[J]. Cancer Cell,2014,25(3):304-317.
[32] Wu GS.The functional interactions between the p53 and MAPK signaling pathways[J]. Cancer Biol Ther,2004,3(2):156-161.
[33] Sauer L, Gitenay D, Vo C, et al.Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cells[J]. Oncogene,2010,29(18):2628-2637.
[34] Muller PA, Trinidad AG, Timpson P, et al.Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion[J]. Oncogene,2013,32(10):1252-1265.
[35] Najem A, Krayem M, Salès F, et al.P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition[J]. Eur J Cancer,2017,83:154-165.
Options
Outlines

/

〈 〉